{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:46:13Z","timestamp":1772585173295,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10620-018-5429-1","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T08:02:33Z","timestamp":1546416153000},"page":"1612-1621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse"],"prefix":"10.1007","volume":"64","author":[{"given":"Marisa","family":"Iborra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Herreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Maia","family":"Bosc\u00e1-Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galo","family":"Trejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Cerrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Herv\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"M\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Nos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"key":"5429_CR1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"M Harbord","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D, et al. European Crohn\u2019s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769\u2013784.","journal-title":"J Crohns Colitis"},{"key":"5429_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V, et al. ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3\u201325.","journal-title":"J Crohns Colitis"},{"key":"5429_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4292\/wjgpt.v8.i2.103","volume":"8","author":"KS Sultan","year":"2017","unstructured":"Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2017;8:103\u2013113.","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"5429_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.cgh.2012.10.038","volume":"11","author":"M Camus","year":"2013","unstructured":"Camus M, Seksik P, Bourrier A, et al. Long-term outcome of patients with Crohn\u2019s disease who respond to azathioprine. Clin Gastroenterol Hepatol. 2013;11:389\u2013394.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5429_CR5","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","volume":"21","author":"U Kopylov","year":"2015","unstructured":"Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a quebec claims database study. Inflamm Bowel Dis. 2015;21:1847\u20131853.","journal-title":"Inflamm Bowel Dis"},{"key":"5429_CR6","doi-asserted-by":"publisher","first-page":"36.e1","DOI":"10.1016\/j.cgh.2010.09.016","volume":"9","author":"DS Kotlyar","year":"2011","unstructured":"Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36.e1\u201341.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5429_CR7","first-page":"704","volume":"12","author":"EV Loftus Jr","year":"2016","unstructured":"Loftus EV Jr. Update on the incidence and prevalence of inflammatory bowel disease in the united states. Gastroenterol Hepatol (N Y). 2016;12:704\u2013707.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"5429_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","volume":"12","author":"G Doherty","year":"2018","unstructured":"Doherty G, Katsanos KH, Burisch J, et al. European Crohn\u2019s and colitis organisation topical review on treatment withdrawal (\u2018exit strategies\u2019) in inflammatory bowel disease. J Crohns Colitis. 2018;12:17\u201331.","journal-title":"J Crohns Colitis"},{"key":"5429_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/00365528909091339","volume":"170","author":"JE Lennard-Jones","year":"1989","unstructured":"Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2\u20136. (Discussion 16-9).","journal-title":"Scand J Gastroenterol Suppl"},{"key":"5429_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro F, Gionchetti P, Eliakim R, et al. European Crohn\u2019s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649\u2013670.","journal-title":"J Crohns Colitis"},{"key":"5429_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.crohns.2013.04.013","volume":"7","author":"V Pittet","year":"2013","unstructured":"Pittet V, Froehlich F, Maillard MH, et al. EPACT-II Update Panellists. When do we dare to stop biological or immunomodulatory therapy for Crohn\u2019s disease? Results of a multidisciplinary European expert panel. J Crohns Colitis. 2013;7:820\u2013826.","journal-title":"J Crohns Colitis"},{"key":"5429_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/apt.12838","volume":"40","author":"B Pariente","year":"2014","unstructured":"Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;40:338\u2013353.","journal-title":"Aliment Pharmacol Ther"},{"key":"5429_CR13","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1097\/MIB.0000000000000400","volume":"21","author":"E Moreno-Rinc\u00f3n","year":"2015","unstructured":"Moreno-Rinc\u00f3n E, Ben\u00edtez JM, Serrano-Ruiz FJ, et al. Prognosis of patients with ulcerative colitis in sustained remission after thiopurines withdrawal. Inflamm Bowel Dis. 2015;21:1564\u20131571.","journal-title":"Inflamm Bowel Dis"},{"key":"5429_CR14","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1038\/ajg.2009.410","volume":"104","author":"A Cassinotti","year":"2009","unstructured":"Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol. 2009;104:2760\u20132776.","journal-title":"Am J Gastroenterol"},{"key":"5429_CR15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/gut.35.3.360","volume":"35","author":"P Munkholm","year":"1994","unstructured":"Munkholm P, Langholz E, Davidsen M, Bionder V. Frequency of glucocorticoid resistance and dependency in Crohn\u2019s disease. Gut. 1994;35:360\u2013362.","journal-title":"Gut"},{"key":"5429_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/gast.2001.26279","volume":"121","author":"WA Faubion Jr","year":"2001","unstructured":"Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255\u2013260.","journal-title":"Gastroenterology"},{"key":"5429_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1097\/01.mib.0000235835.32176.85","volume":"12","author":"J Tung","year":"2006","unstructured":"Tung J, Loftus EV Jr, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn\u2019s disease and ulcerative colitis. Inflamm Bowel Dis. 2006;12:1093\u20131100.","journal-title":"Inflamm Bowel Dis"},{"key":"5429_CR18","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/MIB.0b013e318281d697","volume":"19","author":"J Cosnes","year":"2013","unstructured":"Cosnes J, Seksik P. Early azathioprine in Crohn\u2019s disease. Inflamm Bowel Dis. 2013;19:674\u2013675.","journal-title":"Inflamm Bowel Dis"},{"key":"5429_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/flgastro-2016-100749","volume":"8","author":"A O\u2019Connor","year":"2017","unstructured":"O\u2019Connor A, Hamlin PJ, Taylor J, Selinger C, Scott N, Ford AC. Postoperative prophylaxis in Crohn\u2019s disease after intestinal resection: a retrospective analysis. Frontline Gastroenterol. 2017;8:203\u2013209.","journal-title":"Frontline Gastroenterol"},{"key":"5429_CR20","doi-asserted-by":"publisher","first-page":"441.e1","DOI":"10.1053\/j.gastro.2008.10.051","volume":"136","author":"M Regueiro","year":"2009","unstructured":"Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn\u2019s disease recurrence after ileal resection. Gastroenterology. 2009;136:441.e1\u2013450.e1. (Quiz 716).","journal-title":"Gastroenterology"},{"key":"5429_CR21","doi-asserted-by":"publisher","first-page":"1494.e1","DOI":"10.1016\/j.cgh.2014.03.002","volume":"12","author":"M Regueiro","year":"2014","unstructured":"Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn\u2019s disease recurrence. Clin Gastroenterol Hepatol. 2014;12:1494.e1\u20131502.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5429_CR22","first-page":"591.e1","volume":"8","author":"D Sorrentino","year":"2010","unstructured":"Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2010;8:591.e1\u2013599.e1. (Quiz e78-9).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5429_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1053\/j.gastro.2011.11.011","volume":"142","author":"E Louis","year":"2012","unstructured":"Louis E, Panes J. Adalimumab in ulcerative colitis: can pharmacodynamics be improved based on pharmacokinetics? Gastroenterology. 2012;142:176\u2013178.","journal-title":"Gastroenterology"},{"key":"5429_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cgh.2008.08.028","volume":"7","author":"X Treton","year":"2009","unstructured":"Treton X, Bouhnik Y, Mary JY, et al. Groupe D\u2019Etude Th\u00e9rapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID). Azathioprine withdrawal in patients with Crohn\u2019s disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009;7:80\u201385.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5429_CR25","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/apt.12980","volume":"40","author":"NA Kennedy","year":"2014","unstructured":"Kennedy NA, Kalla R, Warner B, et al. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther. 2014;40:1313\u20131323.","journal-title":"Aliment Pharmacol Ther"},{"key":"5429_CR26","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s10620-014-3419-5","volume":"60","author":"HH Wenzl","year":"2015","unstructured":"Wenzl HH, Primas C, Novacek G, et al. Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn\u2019s disease. Dig Dis Sci. 2015;60:1414\u20131423.","journal-title":"Dig Dis Sci"},{"key":"5429_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.giec.2016.06.005","volume":"26","author":"M Iborra","year":"2016","unstructured":"Iborra M, Beltran B, Nos P. Noninvasive testing for mucosal inflammation in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2016;26:641\u2013656.","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"5429_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/1756283X14553384","volume":"8","author":"FS Lehmann","year":"2015","unstructured":"Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8:23\u201336.","journal-title":"Therap Adv Gastroenterol"},{"key":"5429_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/bmj.305.6844.20","volume":"305","author":"AB Hawthorne","year":"1992","unstructured":"Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20\u201322.","journal-title":"BMJ"},{"key":"5429_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0140-6736(96)90402-X","volume":"347","author":"Y Bouhnik","year":"1996","unstructured":"Bouhnik Y, L\u00e9mann M, Mary JY, et al. Long-term follow-up of patients with Crohn\u2019s disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215\u2013219.","journal-title":"Lancet"},{"key":"5429_CR31","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/gut.50.4.485","volume":"50","author":"AG Fraser","year":"2002","unstructured":"Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30-year review. Gut. 2002;50:485\u2013489.","journal-title":"Gut"},{"key":"5429_CR32","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/j.1365-2036.2004.01944.x","volume":"19","author":"M Vilien","year":"2004","unstructured":"Vilien M, Dahlerup JF, Munck LK, N\u00f8rregaard P, Gr\u00f8nbaek K, Fallingborg J. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn\u2019s disease: increased relapse rate the following year. Aliment Pharmacol Ther. 2004;19:1147\u20131152.","journal-title":"Aliment Pharmacol Ther"},{"key":"5429_CR33","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1053\/j.gastro.2005.03.031","volume":"128","author":"M L\u00e9mann","year":"2005","unstructured":"L\u00e9mann M, Mary JY, Colombel JF, et al. Groupe D\u2019Etude Th\u00e9rapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn\u2019s disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812\u20131818.","journal-title":"Gastroenterology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5429-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5429-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5429-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T19:14:15Z","timestamp":1577906055000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5429-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5429"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5429-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,2]]},"assertion":[{"value":"4 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M Iborra has served as a speaker and consultant from MSD and Takeda. J. Herreras declares no conflict of interest. M. Bosc\u00e1-Watts reports educational activities, research projects, scientific meetings, and advisory boards sponsored by MSD, Ferring, AbbVie, Janssen, and Takeda. X. Cort\u00e9s declares no conflict of interest. G. Trejo declares no conflict of interest. E. Cerrillo declares no conflict of interest. D. Herv\u00e1s declares no conflict of interest. M. M\u00ednguez has served as a speaker, or has received research or education funding from MSD, AbbVie, Takeda, Janssen, and Allergan. B. Beltr\u00e1n reports educational activities, research projects, scientific meetings, and advisory boards sponsored by MSD, Ferring, Otsuka, and Takeda. P. Nos reports grants and personal fees from MSD, grants from Otsuka, AbbVie, and personal fees from Takeda, Kern, Biogen, and Ferring.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}